MBP-8298

a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis

Also Known As:

Dirucotide; L-alpha-aspartyl-L-alpha-glutamyl-L-asparaginyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-phenylalanyl-L-phenylalanyl-L-lysyl-L-asparaginyl-L-isoleucyl-L-valyl-L-threonyl-L-prolyl-L-arginyl-L-threonine; MBP8298

Networked: 6 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Myelin Proteins: 746
      - Myelin Basic Protein: 2422
        MBP-8298: 6
  - Nerve Tissue Proteins: 2
    - Myelin Proteins: 746
      - Myelin Basic Protein: 2422
        MBP-8298: 6
- Peptides: 82426
  - Peptide Fragments: 373
    - MBP-8298: 6

Experts

1.	Apostolopoulos, Vasso: 1 article (12/2018)
2.	Christopoulou, Konstantina: 1 article (12/2018)
3.	Deraos, George: 1 article (12/2018)
4.	Kalbacher, Hubert: 1 article (12/2018)
5.	Kritsi, Eftichia: 1 article (12/2018)
6.	Matsoukas, John: 1 article (12/2018)
7.	Matsoukas, Minos-Timotheos: 1 article (12/2018)
8.	Zoumpoulakis, Panagiotis: 1 article (12/2018)
9.	Boudesocque, Leslie: 1 article (09/2017)
10.	Forni, Luciano: 1 article (09/2017)

Related Diseases

1.	Multiple Sclerosis 12/04/2018 - "Design of Linear and Cyclic Mutant Analogues of Dirucotide Peptide (MBP82⁻98) against Multiple Sclerosis: Conformational and Binding Studies to MHC Class II." 09/01/2017 - "Dirucotide is a synthetic drug candidate for the treatment of multiple sclerosis. " 08/01/2006 - "Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment." 08/01/2007 - "BioMS Medical Corp, under license from the University of Alberta, is developing MBP-8298, a synthetic peptide analog of myelin basic protein, for the potential treatment of multiple sclerosis. " 08/01/2007 - "MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis."
2.	Chronic Progressive Multiple Sclerosis 10/18/2011 - "To evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis (SPMS) who express human leukocyte antigen (HLA) haplotype DR2 or DR4 (DR2(+) or DR4(+)). " 11/01/2012 - "In this study, chronic progressive multiple sclerosis (CPMS) patients receiving the experimental drug MBP8298, on a compassionate care trial, were examined before and after high dose peptide treatment for their circulating regulatory T-cell numbers and their responses to the common mitogens, phytohemagglutinin and poke-weed mitogen. "
3.	Disease Progression 08/01/2006 - "Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment."

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	Phytohemagglutinins
3.	Mitogens
4.	4-chlorophenyl methyl sulfide (CPMS)
5.	HLA Antigens (Human Leukocyte Antigens)
6.	Myelin Basic Protein
7.	Synthetic Drugs